Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.39 |
| ▸ | MGAT2 | Q10469 | 8/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11914066 | 0.92 | EPHX2 (0.43) | EPHX2L3MBTL1ACACB | |
| SCHEMBL11918317 | 0.82 | L3MBTL1 (0.51) | MGAT2EPHX2L3MBTL1 | |
| SCHEMBL19398567 | 0.80 | APP (0.40) | ACACB | |
| SCHEMBL10141615 | 0.80 | ACACB (0.42) | L3MBTL1ACACB | |
| SCHEMBL4550384 | 0.80 | EPHX2 (0.41) | EPHX2ACACB | |
| Hydrochloric Acid SCHEMBL2714794 | 0.79 | EPHX2 (0.41) | EPHX2ACACB | |
| SCHEMBL23468024 | 0.79 | ACACB (0.39) | ACACB | |
| SCHEMBL15034210 | 0.79 | PTGDR2 (0.46) | PTGDR2MGAT2EPHX2L3MBTL1MAOB | |
| SCHEMBL10141613 | 0.78 | ACACB (0.49) | ACACB | |
| SCHEMBL20216138 | 0.77 | PIK3CD (0.40) | ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED | 2017-09-14 | — | — | US | disclosed |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | PTGDR2 2028/4885MGAT2 3854/4885EPHX2 4054/4885 |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | PTGDR2 2028/4885MGAT2 3854/4885EPHX2 4054/4885 |
| US-20170260175-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | PTGDR2 2028/4885MGAT2 3854/4885EPHX2 4054/4885 |
| US-10183933-B2 | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | PIK3CD, PIK3CA, PIK3R5 | PTGDR2 2028/4885MGAT2 3854/4885EPHX2 4054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.